US 11,655,212 B2
Using adiponectin receptor agonists to treat inflammation and bone diseases in diabetes
Jinkun Chen, Lexington, MA (US); Qisheng Tu, Newton, MA (US); Xingwen Wu, Boston, MA (US); Gang Chen, Shanghai (CN); and Wei Qiu, Boston, MA (US)
Assigned to Trustees of Tufts College, Medford, MA (US)
Filed by Trustees of Tufts College, Medford, MA (US)
Filed on Dec. 14, 2021, as Appl. No. 17/550,834.
Claims priority of provisional application 63/125,362, filed on Dec. 14, 2020.
Prior Publication US 2022/0185777 A1, Jun. 16, 2022
Int. Cl. C07D 211/58 (2006.01); A61P 29/00 (2006.01); A61P 19/08 (2006.01)
CPC C07D 211/58 (2013.01) [A61P 19/08 (2018.01); A61P 29/00 (2018.01)] 20 Claims
 
1. A compound of formula

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt thereof,
wherein R1 is —C(═O)R4; R4 is a halo-substituted phenyl, an unsubstituted phenyl, or a C1-C4 alkyl; R2 is a C1-C4 alkoxyl, hydrogen, or a halo; and R3 is hydrogen or a C1-C4 alkyl; or
wherein R1 is an unsubstituted phenyl; R2 is a C1-C4 alkoxyl or hydrogen; and R3 is hydrogen or a C1-C4 alkyl; and
wherein
if R1 is —C(═O)R4 and R4 is a 4-chloro substituted phenyl, R2 and R3 are not both hydrogen;
if R1 is —C(═O)R4 and R4 is the unsubstituted phenyl, (i) R2 and R3 are not both hydrogen or (ii) R2 and R3 are not respectively 4-chloro and hydrogen;
if R1 is —C(═O)R4 and R4 is methyl, R2 and R3 are not respectively 3,4-dichloro and hydrogen, 3,4-dichloro and hydrogen, or 4-bromo and hydrogen;
if R1 is —C(═O)R4 and R4 is ethyl, R2 and R3 are not respectively 3,4-dichloro and hydrogen; and
if R1 is phenyl, R2 and R3 are not respectively hydrogen and methyl.